A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab and/or Ipilimumab in Advanced Solid Tumors

Trial Profile

A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab and/or Ipilimumab in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs BMS 986178 (Primary) ; Ipilimumab; Nivolumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Mar 2018 Planned primary completion date changed from 13 May 2021 to 12 May 2021.
    • 14 Mar 2018 According to the Bristol-Myers Squibb media release, data from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
    • 13 Feb 2018 Planned End Date changed from 22 May 2020 to 15 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top